EyeGate Pharma Hits Primary Endpoint in PRK Pivotal Study

Stock Information for AB Corporate Bond ETF

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About AB Corporate Bond ETF

Kazia Therapeutics (KZIA): EVT801 Data Published in Peer-Reviewed Journal
ReNeuron Group (RENE): Pushing on with CustomEx in H123
EyeGate Pharmaceuticals Appoints Eric J. Daniels, MD, MBA, as Chief Development Officer and Closes Acquisition of Bayon Therapeutics, Inc.
EyeGate to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
EyeGate Pharma Completes Target Enrollment in Phase 2 Proof-of-Concept Study to Evaluate PP-001 for the Treatment of Ocular Surface Inflammation
EyeGate Pharma Reports Second Quarter 2021 Financial Results and Provides Business Update
EyeGate Announces Closing of $10.75 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
EyeGate Announces $10.75 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.